Clinical Trials Logo

ITP clinical trials

View clinical trials related to ITP.

Filter by:

NCT ID: NCT04703621 Active, not recruiting - ITP Clinical Trials

The DART Study- Daratumumab Treatment in ITP

Start date: January 21, 2021
Phase: Phase 2
Study type: Interventional

A multicenter clinical, open-label total dose-escalating phase II study with safety run-in to explore the clinical activity, total dosage, and safety of daratumumab in adult ITP patients who have not responded adequately or relapsed after corticosteroids and at least one second-line therapy including rituximab and/or TPO-RA.

NCT ID: NCT04482777 Not yet recruiting - ITP Clinical Trials

IL37,Tlymphocytes,NK Cells in Pathogenesis of ITP

Start date: July 30, 2023
Phase:
Study type: Observational

To evaluate the role of IL37 in pathogenesis of ITP and to study the relation between IL37,Tlymphocytes,NK cells in ITP

NCT ID: NCT04089267 Completed - ITP Clinical Trials

Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP)

Start date: December 2016
Phase: Phase 4
Study type: Interventional

This is a review of the efficacy and safety of different recombinant human thrombopoietin (rhTPO) regimens in the treatment of patients with primary immune thrombocytopenia (ITP).

NCT ID: NCT02914054 Completed - ITP Clinical Trials

Therapy of Adults Affected by Idiopathic Thrombocytopenic Purpura With Dexamethasone

Start date: October 1, 2016
Phase: Phase 2/Phase 3
Study type: Interventional

In this prospective, randomized, controlled clinical trial investigators' aim was to compare the efficacy and the adverse effect of 3 therapy cycles of HD-DXM versus conventional treatment with PDN for untreated adult patients with ITP. In this study standardized criteria and definitions were used according to consensus international working group guideline for ITPto compare clinical outcomes of the two corticosteroid treatment regimens and determine the superior regimen as a first line strategy for new primary ITP in adults